250 related articles for article (PubMed ID: 10738843)
21. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.
Klugman KP; Dagan R
Antimicrob Agents Chemother; 1995 May; 39(5):1140-6. PubMed ID: 7625802
[TBL] [Abstract][Full Text] [Related]
22. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
[TBL] [Abstract][Full Text] [Related]
23. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.
Karadeniz C; Oğuz A; Canter B; Serdaroğlu A
Pediatr Hematol Oncol; 2000; 17(7):585-90. PubMed ID: 11033734
[TBL] [Abstract][Full Text] [Related]
24. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
[TBL] [Abstract][Full Text] [Related]
25. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
Nelson WK; Rayback PA; Quinones R; Giller RH
Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052
[TBL] [Abstract][Full Text] [Related]
26. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A; Meli EZ; Mazzocchi P; Speranza V
Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
[TBL] [Abstract][Full Text] [Related]
27. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
[TBL] [Abstract][Full Text] [Related]
28. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
Embil JM; Soto NE; Melnick DA
Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
[TBL] [Abstract][Full Text] [Related]
29. Changing role of carbapenems in the treatment of lower respiratory tract infections.
Lode H; Hamacher J; Eller J; Schaberg T
Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
[TBL] [Abstract][Full Text] [Related]
30. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
Hou F; Wu G; Zheng B
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
[TBL] [Abstract][Full Text] [Related]
31. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
Wu Y; Chen K; Shi Z; Wang Q
Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
[TBL] [Abstract][Full Text] [Related]
32. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.
Zanetti G; Bally F; Greub G; Garbino J; Kinge T; Lew D; Romand JA; Bille J; Aymon D; Stratchounski L; Krawczyk L; Rubinstein E; Schaller MD; Chiolero R; Glauser MP; Cometta A;
Antimicrob Agents Chemother; 2003 Nov; 47(11):3442-7. PubMed ID: 14576100
[TBL] [Abstract][Full Text] [Related]
33. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
34. Is it safe to use carbapenems in patients with a history of allergy to penicillin?
Sodhi M; Axtell SS; Callahan J; Shekar R
J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083
[TBL] [Abstract][Full Text] [Related]
35. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.
Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P
J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636
[TBL] [Abstract][Full Text] [Related]
36. Carbapenem treatment of meningitis.
Klugman KP; Dagan R
Scand J Infect Dis Suppl; 1995; 96():45-8. PubMed ID: 7652503
[TBL] [Abstract][Full Text] [Related]
37. Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime.
Ho A; Leung R; Lai CK; Chan TH; Chan CH
Respiration; 1997; 64(3):224-8. PubMed ID: 9154675
[TBL] [Abstract][Full Text] [Related]
38. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.
Schmutzhard E; Williams KJ; Vukmirovits G; Chmelik V; Pfausler B; Featherstone A
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():85-97. PubMed ID: 8543502
[TBL] [Abstract][Full Text] [Related]
39. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem.
Norrby SR; Gildon KM
Scand J Infect Dis; 1999; 31(1):3-10. PubMed ID: 10381210
[TBL] [Abstract][Full Text] [Related]
40. [The role of carbapenems in the treatment of nosocomial infection].
Martínez Lacasa J; Garau J
Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():78-85. PubMed ID: 9410075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
